Evaluation of Sienna Cancer Diagnostics hTERT Antibody on 500 Consecutive Urinary Tract Specimens

被引:5
作者
Allison, Derek B. [1 ]
Sharma, Rajni [1 ]
Cowan, Morgan L. [1 ]
VandenBussche, Christopher J. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
关键词
Urine cytology; Urinary tract; Telomerase; Ancillary test; TERT PROMOTER MUTATIONS; HOPKINS HOSPITAL TEMPLATE; TELOMERASE ACTIVITY; BLADDER-CANCER; HIGH PREVALENCE; PARIS SYSTEM; CYTOLOGY; CARCINOMA; SAMPLES;
D O I
10.1159/000489181
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Telomerase activity can be detected in up to 90% of urothelial carcinomas (UC). Telomerase activity can also be detected in urinary tract cytology (UTC) specimens and indicate an increased risk of UC. We evaluated the performance of a commercially available antibody that putatively binds the telomerase reverse transcriptase (hTERT) subunit on 500 UTC specimens. Study Design: Unstained Cytospin (TM) preparations were created from residual urine specimens and were stained using the anti-hTERT antibody (SCDA7). Two algorithms were developed for concatenating the hTERT result and cytologic diagnosis: a "no indeterminates algorithm," in which a negative cytology and positive hTERT result are considered positive, and a "high-specificity algorithm," in which a negative cytology and positive hTERT result are considered indeterminate (and thus negative for comparison to the gold standard). Results: The "no indeterminates algorithm" and "high-specificity algorithm" yielded a sensitivity of 60.6 and 52.1%, a specificity of 70.4 and 90.7%, a positive predictive value of 39.1 and 63.8%, and a negative predictive value of 85.0 and 85.8%, respectively. Conclusions: A positive hTERT result may identify a subset of patients with an increased risk of high-grade UC (HGUC) who may otherwise not be closely followed, while a negative hTERT immunocytochemistry result is associated with a reduction in risk for HGUC. (c) 2018 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:302 / 310
页数:9
相关论文
共 24 条
  • [1] Clinical model of lifetime cost of treating bladder cancer and associated complications
    Avritscher, Elenir B. C.
    Cooksley, Catherine D.
    Grossman, H. Barton
    Sabichi, Anita L.
    Hamblin, Lois
    Dinney, Colin P.
    Elting, Linda S.
    [J]. UROLOGY, 2006, 68 (03) : 549 - 553
  • [2] The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology
    Barkan, Guliz A.
    Wojcik, Eva M.
    Nayar, Ritu
    Savic-Prince, Spasenija
    Quek, Marcus L.
    Kurtycz, Daniel F. I.
    Rosenthal, Dorothy L.
    [J]. ACTA CYTOLOGICA, 2016, 60 (03) : 185 - 197
  • [3] Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79
  • [4] Prevalence of Telomerase Activity in Human Cancer
    Chen, Chi-Hau
    Chen, Ruey-Jien
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2011, 110 (05) : 275 - 289
  • [5] High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder
    Cowan, Morgan
    Springer, Simeon
    Nguyen, Doreen
    Taheri, Diana
    Guner, Gunes
    Rodriguez, Maria Angelica Mendoza
    Wang, Yuxuan
    Kinde, Isaac
    VandenBussche, Christopher J.
    Olson, Matthew T.
    Cunha, Isabela
    Fujita, Kazutoshi
    Ertoy, Dilek
    Bivalacqua, Trinity J.
    Kinzler, Kenneth
    Vogelstein, Bert
    Netto, George J.
    Papadopoulos, Nickolas
    [J]. MODERN PATHOLOGY, 2016, 29 (05) : 511 - 515
  • [6] Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder
    Cowan, Morgan L.
    Springer, Simeon
    Nguyen, Doreen
    Taheri, Diana
    Guner, Gunes
    Rodriguez, Maria Angelica Mendoza
    Wang, Yuxuan
    Kinde, Isaac
    Pena, Maria Del Carmen Rodriguez
    VandenBussche, Christopher J.
    Olson, Mathew T.
    Cunha, Isabela
    Fujita, Kazutoshi
    Ertoy, Dilek
    Kinzler, Kenneth
    Bivalacqua, Trinity
    Papadopoulos, Nickolas
    Vogelstein, Bert
    Netto, George J.
    [J]. HUMAN PATHOLOGY, 2016, 53 : 8 - 13
  • [7] SUPERFICIAL BLADDER-CANCER - PROGRESSION AND RECURRENCE
    HENEY, NM
    AHMED, S
    FLANAGAN, MJ
    FRABLE, W
    CORDER, MP
    HAFERMANN, MD
    HAWKINS, IR
    [J]. JOURNAL OF UROLOGY, 1983, 130 (06) : 1083 - 1086
  • [8] Significant telomere reduction in human superficial transitional cell carcinoma
    Kamata, S
    Kageyama, Y
    Yonese, J
    Oshima, H
    [J]. BRITISH JOURNAL OF UROLOGY, 1996, 78 (05): : 704 - 708
  • [9] Khalbuss Walid, 2006, Cytojournal, V3, P18, DOI 10.1186/1742-6413-3-18
  • [10] TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
    Kinde, Isaac
    Munari, Enrico
    Faraj, Sheila F.
    Hruban, Ralph H.
    Schoenberg, Mark
    Bivalacqua, Trinity
    Allaf, Mohamad
    Springer, Simeon
    Wang, Yuxuan
    Diaz, Luis A., Jr.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Papadopoulos, Nickolas
    Netto, George J.
    [J]. CANCER RESEARCH, 2013, 73 (24) : 7162 - 7167